Identification of a novel e8/a4 BCR/ABL fusion transcript in a case of a transformed Sézary syndrome
This report deals with a case of Sézary syndrome, a rare peripheral T-cell lymphoproliferative disorder, in which cytogenetic analysis performed during the disease transformation revealed the presence of a t(9;22) (q34;q11.2) translocation. Molecular analyses identified a new transcript, an e8a4 BCR-ABL fusion mRNA which could be responsible for the disease transformation. Figure 1A ). Reverse transcription (RT) and quantitative real-time polymerase chain reaction (RQ-PCR) were performed on the same sample according to Standardised EAC (European Against Cancer) protocols previously reported 6 and expressed as BCR-ABL/ABL ratios according to the international scale now required. 7 The transcripts detected in the patient using the M-primers were quantified at the BCR-ABL/ABL rate of 0.8% which was not in keeping with the cytogenetic results positive in 52% of interphase nuclei. The direct sequencing of these PCR products showed an e15a2 fusion transcript with no preservation of the open reading frame (ORF). A larger PCR analysis using a forward primer in the BCR gene (ENF402 6 ) and a reverse primer (5'GCCCTCGTACAC-CTCCCCGTA3') in the ABL exon a4 revealed an atypical e8a4 after direct sequencing ( Figure 1B) . However, unlike the e8a2 transcripts previously described, [8] [9] [10] the direct junction between BCR exon e8 and ABL exon a4 led to the preservation of the ORF encompassing the whole oncogenic domains of the ABL tyrosine kinase. The quantification of the e8a4 was carried out using RQ-PCR with an e8 forward primer from BCR gene, 10 the same reverse primer and a new probe (FAM 5'TCTACGTCTC-CTCCGAGAGC3'TAMRA) in ABL exon a4. With a serial 10-fold dilution series for e8a4 cDNA from the patient's sample, the assay was found to be linear over at The number of e8a4 copies in the non diluted sample was estimated to be 13,600 for 10,000 copies of ABL which agreed with data obtained by cytogenetic analysis and confirmed that the e8a4 must be the oncogenic fusion transcript. The detection of minority e15a2 spliceoforms suggests that the breakpoint could be located downstream of the Major breakpoint. This genomic rearrangement could then produce multiple spliceoforms without ORF and then undergo nonsense-mediated mRNA decay as previously described. Unfortunately, no retrospective studies of the rearrangement could be performed at diagnosis because of lack of available frozen material.
Since this observation occurred in 1999, before the imatinib era, the clinical outcome for patients bearing this unusual e8a4 transcript could not be predicted. It has to be underlined that the RQ-PCR method designed here is able to detect all known BCR-ABL variants and could represent as an interesting molecular strategy for patients with Ph + cytogenetic but negative molecular analyses. Indeed, the previous case of Ph + lymphoma did not show BCR-ABL rearrangement at molecular level. 4 Therefore, it is possible that this case may correspond to this rare e8a4 transcript. Further studies of unusual BCR-ABL junctions and their associated diseases are required to gain further insight into their pathologic consequences and their sensitivity to new tyrosine kinase inhibitors.
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